Jessica Fye
Stock Analyst at JP Morgan
(3.71)
# 654
Out of 4,479 analysts
100
Total ratings
55.56%
Success rate
4.67%
Average return
Main Sectors:
37 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Overweight | $55 → $72 | $64.50 | +11.63% | 3 | Jun 20, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $31 → $39 | $33.68 | +15.80% | 3 | Jun 18, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Overweight | $75 → $78 | $68.54 | +13.80% | 4 | Jun 12, 2024 | |
| UTHR United Therapeutics | Maintains: Overweight | $280 → $300 | $317.05 | -5.38% | 6 | May 21, 2024 | |
| ASND Ascendis Pharma | Maintains: Overweight | $167 → $170 | $136.27 | +24.75% | 3 | May 3, 2024 | |
| STOK Stoke Therapeutics | Maintains: Neutral | $6 → $13 | $12.83 | +1.33% | 2 | Mar 26, 2024 | |
| BNTX BioNTech SE | Maintains: Underweight | $99 → $90 | $78.76 | +14.27% | 5 | Mar 22, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $170 → $190 | $105.09 | +80.80% | 2 | Mar 22, 2024 | |
| IMCR Immunocore Holdings | Maintains: Overweight | $60 → $70 | $34.80 | +101.15% | 3 | Mar 20, 2024 | |
| BGNE BeiGene | Maintains: Overweight | $184 → $186 | $143.93 | +29.23% | 2 | Mar 19, 2024 | |
| NVCR NovoCure | Maintains: Neutral | $15 → $17 | $16.80 | +1.19% | 3 | Mar 19, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $438 → $450 | $473.78 | -5.02% | 4 | Feb 6, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $52 → $55 | $45.14 | +21.84% | 1 | Feb 1, 2024 | |
| CERE Cerevel Therapeutics Holdings | Maintains: Neutral | $25 → $45 | $41.23 | +9.14% | 4 | Dec 28, 2023 | |
| MRNA Moderna | Maintains: Neutral | $93 → $90 | $117.07 | -23.12% | 5 | Dec 1, 2023 | |
| NKTR Nektar Therapeutics | Reinstates: Underweight | n/a | $1.17 | - | 3 | Nov 20, 2023 | |
| EBS Emergent BioSolutions | Reinstates: Underweight | n/a | $7.49 | - | 2 | Nov 20, 2023 | |
| ESPR Esperion Therapeutics | Reinstates: Neutral | n/a | $2.34 | - | 6 | Nov 20, 2023 | |
| AMRN Amarin Corporation | Reinstates: Underweight | n/a | $0.71 | - | 2 | Nov 20, 2023 | |
| BCRX BioCryst Pharmaceuticals | Reinstates: Overweight | $10 | $6.55 | +52.67% | 2 | Nov 20, 2023 | |
| CRNX Crinetics Pharmaceuticals | Reinstates: Overweight | $35 | $45.54 | -23.14% | 2 | Nov 20, 2023 | |
| DNLI Denali Therapeutics | Reinstates: Overweight | $28 | $21.74 | +28.79% | 2 | Nov 20, 2023 | |
| ALKS Alkermes | Reinstates: Neutral | $33 | $24.19 | +36.42% | 3 | Nov 20, 2023 | |
| LEGN Legend Biotech | Maintains: Overweight | $65 → $76 | $44.74 | +69.87% | 2 | Apr 19, 2023 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $54 → $52 | $51.30 | +1.36% | 3 | Feb 23, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $80 | $59.02 | +35.55% | 2 | Feb 8, 2023 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $140 → $112 | $82.22 | +36.22% | 1 | Oct 24, 2022 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Neutral | $204 → $200 | $247.61 | -19.23% | 1 | Oct 24, 2022 | |
| CARA Cara Therapeutics | Upgrades: Overweight | $17 → $20 | $0.28 | +7,096.83% | 2 | Mar 8, 2022 | |
| APRE Aprea Therapeutics | Downgrades: Underweight | n/a | $3.80 | - | 1 | Aug 20, 2021 | |
| LVTX LAVA Therapeutics | Initiates: Overweight | n/a | $1.87 | - | 1 | Apr 19, 2021 | |
| LXRX Lexicon Pharmaceuticals | Upgrades: Neutral | n/a | $1.60 | - | 2 | Jan 29, 2021 | |
| MRSN Mersana Therapeutics | Downgrades: Underweight | n/a | $1.86 | - | 4 | Mar 11, 2019 | |
| NVAX Novavax | Downgrades: Underweight | n/a | $12.97 | - | 3 | Feb 28, 2019 | |
| RDUS Radius Health | Maintains: Overweight | n/a | $14.67 | - | 4 | Nov 2, 2018 | |
| CMRX Chimerix | Downgrades: Underweight | n/a | $0.86 | - | 1 | Feb 14, 2018 | |
| ENTA Enanta Pharmaceuticals | Downgrades: Neutral | n/a | $13.45 | - | 1 | Feb 8, 2018 |
Insmed
Jun 20, 2024
Maintains: Overweight
Price Target: $55 → $72
Current: $64.50
Upside: +11.63%
Mirum Pharmaceuticals
Jun 18, 2024
Maintains: Overweight
Price Target: $31 → $39
Current: $33.68
Upside: +15.80%
Intra-Cellular Therapies
Jun 12, 2024
Maintains: Overweight
Price Target: $75 → $78
Current: $68.54
Upside: +13.80%
United Therapeutics
May 21, 2024
Maintains: Overweight
Price Target: $280 → $300
Current: $317.05
Upside: -5.38%
Ascendis Pharma
May 3, 2024
Maintains: Overweight
Price Target: $167 → $170
Current: $136.27
Upside: +24.75%
Stoke Therapeutics
Mar 26, 2024
Maintains: Neutral
Price Target: $6 → $13
Current: $12.83
Upside: +1.33%
BioNTech SE
Mar 22, 2024
Maintains: Underweight
Price Target: $99 → $90
Current: $78.76
Upside: +14.27%
Jazz Pharmaceuticals
Mar 22, 2024
Maintains: Overweight
Price Target: $170 → $190
Current: $105.09
Upside: +80.80%
Immunocore Holdings
Mar 20, 2024
Maintains: Overweight
Price Target: $60 → $70
Current: $34.80
Upside: +101.15%
BeiGene
Mar 19, 2024
Maintains: Overweight
Price Target: $184 → $186
Current: $143.93
Upside: +29.23%
NovoCure
Mar 19, 2024
Maintains: Neutral
Price Target: $15 → $17
Current: $16.80
Upside: +1.19%
Vertex Pharmaceuticals
Feb 6, 2024
Maintains: Overweight
Price Target: $438 → $450
Current: $473.78
Upside: -5.02%
Ionis Pharmaceuticals
Feb 1, 2024
Maintains: Neutral
Price Target: $52 → $55
Current: $45.14
Upside: +21.84%
Cerevel Therapeutics Holdings
Dec 28, 2023
Maintains: Neutral
Price Target: $25 → $45
Current: $41.23
Upside: +9.14%
Moderna
Dec 1, 2023
Maintains: Neutral
Price Target: $93 → $90
Current: $117.07
Upside: -23.12%
Nektar Therapeutics
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $1.17
Upside: -
Emergent BioSolutions
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $7.49
Upside: -
Esperion Therapeutics
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $2.34
Upside: -
Amarin Corporation
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $0.71
Upside: -
BioCryst Pharmaceuticals
Nov 20, 2023
Reinstates: Overweight
Price Target: $10
Current: $6.55
Upside: +52.67%
Crinetics Pharmaceuticals
Nov 20, 2023
Reinstates: Overweight
Price Target: $35
Current: $45.54
Upside: -23.14%
Denali Therapeutics
Nov 20, 2023
Reinstates: Overweight
Price Target: $28
Current: $21.74
Upside: +28.79%
Alkermes
Nov 20, 2023
Reinstates: Neutral
Price Target: $33
Current: $24.19
Upside: +36.42%
Legend Biotech
Apr 19, 2023
Maintains: Overweight
Price Target: $65 → $76
Current: $44.74
Upside: +69.87%
Halozyme Therapeutics
Feb 23, 2023
Maintains: Overweight
Price Target: $54 → $52
Current: $51.30
Upside: +1.36%
Incyte
Feb 8, 2023
Maintains: Neutral
Price Target: $82 → $80
Current: $59.02
Upside: +35.55%
BioMarin Pharmaceutical
Oct 24, 2022
Maintains: Overweight
Price Target: $140 → $112
Current: $82.22
Upside: +36.22%
Alnylam Pharmaceuticals
Oct 24, 2022
Maintains: Neutral
Price Target: $204 → $200
Current: $247.61
Upside: -19.23%
Cara Therapeutics
Mar 8, 2022
Upgrades: Overweight
Price Target: $17 → $20
Current: $0.28
Upside: +7,096.83%
Aprea Therapeutics
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $3.80
Upside: -
LAVA Therapeutics
Apr 19, 2021
Initiates: Overweight
Price Target: n/a
Current: $1.87
Upside: -
Lexicon Pharmaceuticals
Jan 29, 2021
Upgrades: Neutral
Price Target: n/a
Current: $1.60
Upside: -
Mersana Therapeutics
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $1.86
Upside: -
Novavax
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $12.97
Upside: -
Radius Health
Nov 2, 2018
Maintains: Overweight
Price Target: n/a
Current: $14.67
Upside: -
Chimerix
Feb 14, 2018
Downgrades: Underweight
Price Target: n/a
Current: $0.86
Upside: -
Enanta Pharmaceuticals
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $13.45
Upside: -